BioSpace News Archive

AngioDynamics to Report Fiscal 2021 Fourth Quarter and Full-Year Financial Results and Host Investor & Technology Day on July 13, 2021

IQVIA™ (NYSE: IQV) today introduced Clinical Data Analytics Suite (CDAS) , a new SaaS-based clinical data analytics platform that combines structured and unstructured data from clinical trials into a single, standardized setting for easier access and use.

Innovent Biologics, Inc. announces that results of a phase 1 clinical trial of IBI362, a glucagon-like petide-1 and glucagon receptor dual agonist in overweight or obese Chinese participants are presented in an e-poster at the American Diabetes Association 81st Scientific Sessions.

Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced the pricing of its initial public offering of 6,250,000 shares of its common stock at a public offering price of $16.00 per share.

Graphite Bio, Inc., a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced the pricing of its upsized initial public offering of 14,000,000 shares of its common stock at a price to the public of $17.00 per share

Boston Scientific Corporation (NYSE: BSX) announced today the election of David S. Wichmann to its board of directors, effective immediately.

Mirati Therapeutics, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to adagrasib for the potential treatment of patients with non-small cell lung cancer (NSCLC) who harbor the KRAS G12C mutation.

Medicure Inc. is pleased to announce the appointment of Mr. David Gurvey (CPA, CMA, B.Sc.) as Chief Financial Officer.

Adial Pharmaceuticals, Inc. today announced that it has received correspondence related to its request for Fast Track Designation from the U.S. Food and Drug Administration (FDA) for its drug candidate, AD04.

The U.S. Food and Drug Administration issued an emergency use authorization for the drug Actemra for the treatment of hospitalized adults and pediatric patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation.